Literature DB >> 24333516

Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation?

F Cornud1, Gaby Khoury2, Naim Bouazza3, Frederic Beuvon4, Michael Peyromaure5, Thierry Flam5, Marc Zerbib5, Paul Legmann2, Nicolas B Delongchamps5.   

Abstract

PURPOSE: We determined whether endorectal multiparametric magnetic resonance imaging at 1.5 Tesla could predict tumor target volume in the perspective of focal therapy of prostate cancer.
MATERIALS AND METHODS: A total of 84 consecutive patients underwent multiparametric magnetic resonance imaging before radical prostatectomy. The volume of each suspicious area detected on magnetic resonance imaging and of all surgical histological foci was determined by planimetry. We first used each magnetic resonance imaging sequence (T2-weighted, diffusion weighted and dynamic contrast enhanced) and then the sequence showing the largest tumor area (multiparametric volume). Finally, the largest area of any sequence was used to calculate a target volume according to the volume of a cylinder. Agreement between magnetic resonance imaging and pathological findings was assessed by linear regression and residual analysis.
RESULTS: Histology revealed 99 significant tumors with a volume of greater than 0.2 cc and/or a Gleason score of greater than 6. Of the tumors 16 (16.2%) were undetected by multiparametric magnetic resonance imaging. Linear regression analysis showed that tumor volume estimated by T2-weighted or diffusion weighted imaging correlated significantly with pathological volume (r(2) = 0.82 and 0.83, respectively). Residuals from diffusion weighted imaging volume estimations did not significantly differ from 0. Nevertheless, diffusion weighted imaging underestimated pathological volume in 43 of 87 cases (49%) by a mean of 0.56 cc (range 0.005 to 2.84). Multiparametric and target volumes significantly overestimated pathological volume by a mean of 16% and 44% with underestimation in 28 (32%) and 15 cases (17%), respectively. Volume underestimation was significantly higher for tumor foci less than 0.5 cc. The percent of Gleason grade 4 did not influence tumor volume estimation.
CONCLUSIONS: Magnetic resonance imaging can detect most significant tumors. However, delineating a target volume may require further adjustment before planning magnetic resonance imaging targeted focal treatment.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  diagnostic imaging; magnetic resonance imaging; prostate; prostatectomy; prostatic neoplasms

Mesh:

Year:  2013        PMID: 24333516     DOI: 10.1016/j.juro.2013.12.006

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  28 in total

1.  Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer.

Authors:  Nima Nassiri; Daniel J Margolis; Shyam Natarajan; Devi S Sharma; Jiaoti Huang; Frederick J Dorey; Leonard S Marks
Journal:  J Urol       Date:  2016-09-14       Impact factor: 7.450

2.  Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  Clin Transl Imaging       Date:  2017-04-10

Review 3.  Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy and future directions.

Authors:  Hüseyin Cihan Demirel; John Warren Davis
Journal:  Turk J Urol       Date:  2018-03-01

4.  Diffusion-weighted imaging of the prostate: should we use quantitative metrics to better characterize focal lesions originating in the peripheral zone?

Authors:  Thibaut Pierre; Francois Cornud; Loïc Colléter; Frédéric Beuvon; Frantz Foissac; Nicolas B Delongchamps; Paul Legmann
Journal:  Eur Radiol       Date:  2017-11-22       Impact factor: 5.315

Review 5.  Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning.

Authors:  Steven Sidelsky; Shaan Setia; Srinivas Vourganti
Journal:  Curr Urol Rep       Date:  2017-10-18       Impact factor: 3.092

6.  A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy.

Authors:  R Diamand; M Oderda; W Al Hajj Obeid; S Albisinni; R Van Velthoven; G Fasolis; G Simone; M Ferriero; J-B Roche; T Piechaud; A Pastore; A Carbone; G Fiard; J-L Descotes; G Marra; P Gontero; E Altobelli; R Papalia; P Kumar; D Eldred-Evans; A Giacobbe; G Muto; V Lacetera; V Beatrici; T Roumeguere; A Peltier
Journal:  World J Urol       Date:  2019-01-16       Impact factor: 4.226

Review 7.  Current role of multiparametric magnetic resonance imaging for prostate cancer.

Authors:  Romaric Loffroy; Olivier Chevallier; Morgan Moulin; Sylvain Favelier; Pierre-Yves Genson; Pierre Pottecher; Gilles Crehange; Alexandre Cochet; Luc Cormier
Journal:  Quant Imaging Med Surg       Date:  2015-10

8.  A novel biopsy-related parameter derived from location and relationship of positive cores on standard 12-core trans-rectal ultrasound-guided prostate biopsy: a useful parameter for predicting tumor volume compared to number of positive cores.

Authors:  Sangjun Yoo; Hwancheol Son; Sohee Oh; Juhyun Park; Sung Yong Cho; Min Chul Cho; Hyeon Jeong
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-22       Impact factor: 4.553

Review 9.  An update on focal therapy for prostate cancer.

Authors:  Marlon Perera; Nishanth Krishnananthan; Uri Lindner; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2016-09-27       Impact factor: 14.432

Review 10.  The prostate cancer focal therapy.

Authors:  Filippo Pesapane; Francesca Patella; Enrico Maria Fumarola; Edoardo Zanchetta; Chiara Floridi; Gianpaolo Carrafiello; Chloë Standaert
Journal:  Gland Surg       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.